186 related articles for article (PubMed ID: 35999349)
1. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
2. Notch signaling activation induces cell death in MAPKi-resistant melanoma cells.
Mikheil DM; Prabhakar K; Arshad A; Rodriguez CI; Newton MA; Setaluri V
Pigment Cell Melanoma Res; 2019 Jul; 32(4):528-539. PubMed ID: 30614626
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
4. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of
Aloia A; Müllhaupt D; Chabbert CD; Eberhart T; Flückiger-Mangual S; Vukolic A; Eichhoff O; Irmisch A; Alexander LT; Scibona E; Frederick DT; Miao B; Tian T; Cheng C; Kwong LN; Wei Z; Sullivan RJ; Boland GM; Herlyn M; Flaherty KT; Zamboni N; Dummer R; Zhang G; Levesque MP; Krek W; Kovacs WJ
Clin Cancer Res; 2019 Nov; 25(22):6852-6867. PubMed ID: 31375515
[TBL] [Abstract][Full Text] [Related]
5. DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
Gutierrez-Prat N; Zuberer HL; Mangano L; Karimaddini Z; Wolf L; Tyanova S; Wellinger LC; Marbach D; Griesser V; Pettazzoni P; Bischoff JR; Rohle D; Palladino C; Vivanco I
Life Sci Alliance; 2022 Sep; 5(9):. PubMed ID: 35580987
[TBL] [Abstract][Full Text] [Related]
6. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype.
Castro-Pérez E; Rodríguez CI; Mikheil D; Siddique S; McCarthy A; Newton MA; Setaluri V
Stem Cell Reports; 2019 Jul; 13(1):177-192. PubMed ID: 31231022
[TBL] [Abstract][Full Text] [Related]
7. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors.
Richard G; Dalle S; Monet MA; Ligier M; Boespflug A; Pommier RM; de la Fouchardière A; Perier-Muzet M; Depaepe L; Barnault R; Tondeur G; Ansieau S; Thomas E; Bertolotto C; Ballotti R; Mourah S; Battistella M; Lebbé C; Thomas L; Puisieux A; Caramel J
EMBO Mol Med; 2016 Oct; 8(10):1143-1161. PubMed ID: 27596438
[TBL] [Abstract][Full Text] [Related]
8. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
Wu M; Hanly A; Gibson F; Fisher R; Rogers S; Park K; Zuger A; Kuang K; Kalin JH; Nocco S; Cole M; Xiao A; Agus F; Labadorf A; Beck S; Collard M; Cole PA; Alani RM
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38300709
[TBL] [Abstract][Full Text] [Related]
9. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP; Böhi F; Leslie Pedrioli DM; Cheng PF; Ferrari E; Baumgaertner P; Alvarado-Diaz A; Sella F; Cereghetti A; Turko P; Wright RH; De Bock K; Speiser DE; Ferrari R; Levesque MP; Hottiger MO
Cancer Res; 2023 Dec; 83(23):3974-3988. PubMed ID: 37729428
[TBL] [Abstract][Full Text] [Related]
11. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
13. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.
Kfir-Elirachman K; Ortenberg R; Vizel B; Besser MJ; Barshack I; Schachter J; Nemlich Y; Markel G
Neoplasia; 2018 Apr; 20(4):401-409. PubMed ID: 29558679
[TBL] [Abstract][Full Text] [Related]
14. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.
Song K; Minami JK; Huang A; Dehkordi SR; Lomeli SH; Luebeck J; Goodman MH; Moriceau G; Krijgsman O; Dharanipragada P; Ridgley T; Crosson WP; Salazar J; Pazol E; Karin G; Jayaraman R; Balanis NG; Alhani S; Sheu K; Ten Hoeve J; Palermo A; Motika SE; Senaratne TN; Paraiso KH; Hergenrother PJ; Rao PN; Multani AS; Peeper DS; Bafna V; Lo RS; Graeber TG
Cancer Discov; 2022 Apr; 12(4):1046-1069. PubMed ID: 34930786
[TBL] [Abstract][Full Text] [Related]
16. T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
Granados K; Hüser L; Federico A; Sachindra S; Wolff G; Hielscher T; Novak D; Madrigal-Gamboa V; Sun Q; Vierthaler M; Larribère L; Umansky V; Utikal J
Br J Cancer; 2020 Mar; 122(7):1023-1036. PubMed ID: 32063604
[TBL] [Abstract][Full Text] [Related]
17. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
[TBL] [Abstract][Full Text] [Related]
18. Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V; Eichhoff O; Gerner C; Paulitschke P; Bileck A; Mohr T; Cheng PF; Leitner A; Guenova E; Saulite I; Freiberger SN; Irmisch A; Knapp B; Zila N; Chatziisaak TP; Stephan J; Mangana J; Kunstfeld R; Pehamberger H; Aebersold R; Dummer R; Levesque MP
EMBO J; 2019 Aug; 38(15):e95874. PubMed ID: 31267558
[TBL] [Abstract][Full Text] [Related]
19. Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon A; Chaney KE; Milewski D; Williams KB; Williams RL; Choi K; Miller A; Kalin TV; Pressey JG; Szabo S; Azam M; Largaespada DA; Ratner N
Clin Cancer Res; 2019 Jul; 25(13):4117-4127. PubMed ID: 30936125
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
